Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF) bills itself as “a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics.”

The Company owns and operates an umbrella of related businesses, including:

• The largest chain of psychedelic wellness clinics in the U.S., including Ketamine Infusion Centers and Ketamine Wellness Centers
• Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology
• Meet Delic, the premier psychedelic wellness event
• And trusted media and e-commerce platforms Reality Sandwich and Delic Radio

The company is backed by a team of industry and cannabis veterans, and a diverse network, whose mission is to provide education, research, high-quality products and effective treatment options to the masses.

Delic’s growth comes as the firm this week published the results of a new survey conducted by The Harris Poll, which found that nearly two thirds of Americans who suffer from anxiety/depression/PTSD (65%) believe that psychedelic medicine (i.e. ketamine, psilocybin and MDMA) should be made available to patients with treatment-resistant anxiety, depression or PTSD.

According to the survey, conducted online in December 2021 among 953 U.S. adults who suffer from anxiety/depression/PTSD, nearly two-thirds (63%) of Americans who have used prescription medications to treat anxiety/depression/PTSD say that while the medication helped, they still experienced residual feelings of anxiety, depression or PTSD. Furthermore, 18% say that the medication did not improve their condition/made it worse.

“We are witnessing a silent crisis impacting people across the globe exacerbated by an ongoing pandemic, and the results of this survey should compel more medical professionals and lawmakers to support in-depth studies on the therapeutic benefits of psychedelic medicine,” said Matt Stang, co-founder and CEO of Delic.

“This promising family of new medicines has the potential to be more effective than traditional medicines with minimal side effects, giving people their best selves back. Our country’s mental health crisis not only impacts public health, but also the economy – each year, untreated mental illness costs the U.S. up to $300 billion in lost productivity.”

On the back of the findings, we sat down with Stang to discuss the shifting public sentiment towards psychedelic medicine, as well as the company’s targets for 2022 and beyond...